Abstracts tagged "rheumatoid arthritis (RA) and therapy"

Abstract Number: 449 • 2015 ACR/ARHP Annual Meeting
Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)
Ruediger Mueller¹, Michael Gengenbacher², Symi richter³, Jean Dudler⁴, Burkhard Moeller⁵ and Johannes von Kempis⁶, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Bethesdaspital, Basel, Switzerland, ³Bethsdaspital, Basel, Switzerland, ⁴Kantonsspital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Holiday seasons can present a major problem to RA patients treated with weekly subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore an evaluation of the…
Abstract Number: 2371 • 2014 ACR/ARHP Annual Meeting
Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra
Herman F. Mann^1,2, Sarka Forejtova³, Katerina Jarosova⁴, Ladislav Senolt⁵, Jakub Zavada⁶, Michal Uher⁷, Karel Hejduk⁷ and Karel Pavelka⁸, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Revmatologicky ustav, Prague, Czech Republic, ⁶Charles University, Prague, Czech Republic, ⁷Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: The biological disease-modifying anti-rheumatic drugs (bDMARDs) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic DMARDs (csDMARDs). However…
Abstract Number: 1963 • 2014 ACR/ARHP Annual Meeting
Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on: Tissue Inflammation, Organization and Angiogenesis in Autoimmune Arthritis
Siba Raychaudhuri¹, Anupam Mitra², Ananya Datta Mitra³, Christine Abria⁴ and Smriti K. Raychaudhuri³, ¹Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, ²Dermatology, VA Sacramento Medical Center, Mather, CA, ³Rheumatology, VA Sacramento Medical Center, Mather, CA, ⁴Research, VA Sacramento Medical Center, Mather, CA
Background/Purpose: The PI3K/Akt/mTOR signaling proteins are pro-growth/pro-survival and thus likely to regulate inflammatory cascades in autoimmune diseases (1). The key pathologic outcome in psoriatic arthritis…
Abstract Number: 1513 • 2014 ACR/ARHP Annual Meeting
Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge
Frieda A. Koopman¹, Yaakov Levine², Mike Faltys², Ralph Zitnik² and Paul P. Tak³, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²SetPoint Medical Corporation, Valencia, CA, ³Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Cholinergic anti-inflammatory pathway (CAP) activation by electrical vagus nerve stimulation (VNS) is being studied in rheumatoid arthritis (RA) trials (NCT01552941). CAP signaling proceeds sequentially…
Abstract Number: 403 • 2014 ACR/ARHP Annual Meeting
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis
Elisa Gremese, Barbara Tolusso, Anna Laura Fedele, Maria Rita Gigante, Silvia Canestri, Clara Di Mario, Angela Carbonella and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose . Obesity per se is a systemic, low-grade inflammatory state and the adipose tissue is an endocrine organ that releases bioactive substances, including pro-inflammatory…
Abstract Number: 1332 • 2013 ACR/ARHP Annual Meeting
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis
Elisa Gremese, Barbara Tolusso, Anna Laura Fedele, Maria Rita Gigante, Angela Carbonella, Silvia Canestri, Clara Di Mario and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Obesity per se is a systemic, low-grade inflammatory state and the adipose tissue is an endocrine organ that releases bioactive substances, including pro-inflammatory cytokines,…
Abstract Number: 1287 • 2013 ACR/ARHP Annual Meeting
Pre-Clinical Proof-Of-Concept Of ALX-0761, a Nanobody^® Neutralizing Both IL-17A and F In a Cynomolgus Monkey Collagen Induced Arthritis Model
Katrien Vanheusden¹, Laurent Detalle¹, Alex Hemeryck¹, Alain Vicari², Roland Grenningloh³, Sofie Poelmans¹, Heidi Wouters⁴ and Thomas Stöhr¹, ¹Pharmacology, Ablynx NV, Gent, Belgium, ²Calypso Biotech, Geneva, Switzerland, ³Pharmacology, Merck-Serono, Darmstadt, Germany, ⁴Clinical Development, Ablynx nv, Zwijnaarde, Belgium
Background/Purpose: Interleukin (IL)-17 and Th17 cells are implicated in many auto-immune diseases, such as rheumatoid arthritis (RA), psoriasis and multiple sclerosis. Although IL-17(A) is the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.